Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARBLI vs ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.
Spasticity due to multiple sclerosis,Spinal cord injury,Alcohol use disorder (off-label)
Perioperative prophylaxis,Respiratory tract infections,Urinary tract infections,Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis,Genital infections (e.g., prostatitis, epididymitis),Off-label: Surgical prophylaxis in certain procedures
10 mg orally once daily.
For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
1.8 hours (normal renal function); prolonged to 10-30 hours in severe renal impairment (Cr Cl <10 m L/min)
Primarily hydrolyzed by esterases to baclofen; baclofen is minimally metabolized (mainly renal clearance of unchanged drug).
Cefazolin is minimally metabolized; primarily undergoes renal tubular secretion and glomerular filtration. Not significantly metabolized by cytochrome P450 enzymes.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Renal: >80% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <1%
>99% bound to albumin and alpha-1-acid glycoprotein.
80-86% bound to serum albumin
0.7 L/kg, indicating extensive tissue distribution.
0.12-0.16 L/kg; primarily in extracellular fluid
Oral: 70% (range 60-80%); IV: 100%.
IM: ~85% (peak levels in 0.5-2 hours); IV: 100%
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR <30 m L/min/1.73 m²: use not recommended.
Cr Cl 35-54 m L/min: 1-2 g every 8 hours. Cr Cl 11-34 m L/min: 1-2 g every 12 hours. Cr Cl <10 m L/min: 1-2 g every 24-48 hours. For patients on hemodialysis, administer 1-2 g after each dialysis session.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended.
No dosage adjustment required for hepatic impairment. Cefazolin is primarily renally eliminated.
Not established for patients <18 years.
For children >1 month: 25-100 mg/kg/day IV divided every 6-8 hours. For severe infections: up to 100 mg/kg/day IV divided every 6-8 hours. Maximum dose: 6 g/day.
No specific dose adjustment required; monitor renal function.
Adjust dose based on renal function. Calculate Cr Cl and follow renal adjustment guidelines. No additional geriatric-specific modifications beyond renal consideration.
Abrupt discontinuation may precipitate withdrawal reactions including seizures, hallucinations, and life-threatening hyperthermia (similar to baclofen withdrawal).
None
Risk of withdrawal symptoms with abrupt cessation,May cause sedation and dizziness,Use caution in renal impairment,May exacerbate psychiatric disorders,Avoid with alcohol or CNS depressants
Hypersensitivity reactions: Cross-allergenicity with other beta-lactams; caution in penicillin-allergic patients,Acute generalized exanthematous pustulosis (AGEP),Clostridioides difficile-associated diarrhea (CDAD),Seizures at high doses or in renal impairment,Nephrotoxicity (especially with aminoglycosides or loop diuretics),Hemolytic anemia (rare),Interference with glucose and protein tests,Use in renal impairment: dose adjustment required,Pregnancy category B: use only if clearly needed,Geriatric use: increased risk of adverse effects
Hypersensitivity to baclofen or any component of the formulation
Hypersensitivity to cefazolin or any cephalosporin,Severe immediate hypersensitivity (e.g., anaphylaxis) to penicillins or other beta-lactams
Avoid alcohol. No specific food interactions reported, but take with or without food consistently to maintain stable drug levels.
No specific food interactions. Avoid alcohol during therapy and for 72 hours post-treatment due to risk of disulfiram-like reaction (cefazolin has a methylthiotetrazole side chain). Patients with diabetes should account for dextrose content (5 g/100 m L) in their carbohydrate intake.
ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at doses up to 4 times the maximum recommended human dose based on body surface area. However, fetal toxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Based on mechanism (GABAB agonist), potential risk cannot be excluded. First trimester: unknown risk; second/third trimester: possible risk of fetal harm from maternal muscle relaxation; third trimester: risk of neonatal withdrawal (hypotonia, respiratory depression) if used near term.
Pregnancy Category B. No evidence of risk in humans based on animal studies and human data; however, adequate studies in pregnant women are lacking. No known teratogenic effects in first trimester; use only if clearly needed.
No data on excretion in human milk. Arbaclofen is a small molecule (MW 215.68) and likely excreted into breast milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., sedation, respiratory depression) in nursing infants, breastfeeding is not recommended during therapy.
Cefazolin is excreted into breast milk in low concentrations (M/P ratio approximately 0.2-0.5). Considered compatible with breastfeeding; monitor for potential gastrointestinal effects in the infant.
No specific dosing guidelines established for pregnancy due to lack of data. Pregnancy may alter pharmacokinetics (increased volume of distribution, renal clearance) potentially requiring dose adjustments; however, no recommendations can be made because drug is contraindicated in pregnancy.
Increased glomerular filtration rate during pregnancy may require higher doses or more frequent dosing to achieve therapeutic concentrations; specific dose adjustment not established; monitor clinical response.
ARBLI (arbaclofen) is a prodrug of baclofen used for spasticity. Titrate slowly to avoid CNS depression. Monitor renal function; dose adjustment required in Cr Cl <60 m L/min. Avoid abrupt discontinuation due to withdrawal symptoms. Use with caution in patients with history of substance abuse due to abuse potential.
For surgical prophylaxis, administer within 60 minutes before incision. Use extended infusion (over 1-2 hours) for critically ill patients to optimize pharmacokinetic/pharmacodynamic target attainment. Monitor renal function given cefazolin excretion; adjust dose for Cr Cl <55 m L/min. Avoid in patients with immediate-type hypersensitivity to penicillins (10% cross-reactivity risk). In obese patients (BMI ≥40 kg/m²), consider doubling the standard dose (2 g IV) for adequate tissue penetration.
Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking abruptly; gradual dose reduction is necessary to prevent withdrawal symptoms (hallucinations, seizures, rapid heart rate).,Avoid driving or operating heavy machinery until you know how ARBLI affects you, as it may cause dizziness or drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation risk.,Inform your doctor if you have kidney problems, diabetes, or a history of substance abuse.,Store at room temperature away from moisture and heat.
Complete the full course of antibiotics as prescribed, even if you feel better.,Report any signs of allergic reaction (rash, itching, difficulty breathing, swelling of face or throat) to your healthcare provider immediately.,If you are diabetic, note that each 1% dextrose solution provides 3.4 kcal/g; monitor blood glucose levels closely.,The medication is given intravenously; ensure the IV site is clean and free from redness, swelling, or pain.,Avoid alcohol during treatment and for at least 72 hours after the last dose to prevent disulfiram-like reactions (flushing, nausea, vomiting).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARBLI vs ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
ARBLI is a Cephalosporin Antibiotic that works by ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.. ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is a Cephalosporin Antibiotic that works by Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking. This leads to cell lysis and death, primarily in actively dividing bacteria.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARBLI and ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARBLI is: 10 mg orally once daily.. The standard adult dose of ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is: For uncomplicated infections: 1-2 g IV every 8 hours. For severe infections: up to 2 g IV every 4 hours. Administered as an IV infusion over 30-60 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARBLI and ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARBLI is classified as Category C. ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at d. ANCEF IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Pregnancy Category B. No evidence of risk in humans based on animal studies and human data; however, adequate studies in pregnant women are lacking. No known teratogenic effects in. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.